Sign In
Buy PRLD
$3.66
+0.160 (+4.57%)
At Close: Jun 03, 2026
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
04:35pm, Tuesday, 09'th Apr 2024
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
04:45pm, Tuesday, 05'th Mar 2024
WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
04:05pm, Thursday, 29'th Feb 2024
WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will parti
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
04:05pm, Thursday, 15'th Feb 2024
First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024
New Strong Buy Stocks for January 25th
07:41am, Thursday, 25'th Jan 2024
S, ASAN, PRLD, EMKR and SNAP have been added to the Zacks Rank #1 (Strong Buy) List on January 25, 2023.
Prelude Therapeutics Announces $25 Million Private Placement
09:34am, Monday, 11'th Dec 2023
WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced
Prioritization of its first-in-class SMARCA2 degrader and potentially best-in-class CDK9 inhibitor programs for continued clinical development Enters partnership with AbCellera to develop a portfolio
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
12:30pm, Saturday, 14'th Oct 2023
WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinica
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
01:31pm, Wednesday, 04'th Oct 2023
Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
08:30am, Tuesday, 29'th Aug 2023
WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will particip
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
08:00am, Thursday, 03'rd Aug 2023
Four lead programs on track to deliver clinical data and to inform future development plans Recent equity financing extends cash runway into 2026, enabling advancement of Prelude's pipeline through
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
08:30am, Thursday, 27'th Apr 2023
WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will partici
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
08:30am, Tuesday, 11'th Apr 2023
Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline
The 7 Worst Stocks to Buy Now
06:48pm, Saturday, 18'th Mar 2023
Generally, I dislike writing about the worst stocks to buy now (or similar themes) because it invariably offends members of the internet defense league. It's not the greatest experience to receive a f
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
01:46pm, Thursday, 16'th Mar 2023
Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.
